Trial Profile
A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Omipalisib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 14 Feb 2019 Results evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of omipalisib in subjects Idiopathic Pulmonary Fibrosis published in the European Respiratory Journal
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
- 16 Aug 2016 Status changed from recruiting to completed.